Yiqun Shellman
Concepts (321)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 34 | 2024 | 761 | 6.400 |
Why?
| | Skin Neoplasms | 15 | 2024 | 847 | 3.150 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 9 | 2025 | 240 | 2.480 |
Why?
| | Sulfonamides | 7 | 2020 | 580 | 2.010 |
Why?
| | Antineoplastic Agents | 8 | 2025 | 2194 | 1.990 |
Why?
| | Apoptosis | 15 | 2025 | 2430 | 1.940 |
Why?
| | Neoplastic Stem Cells | 5 | 2021 | 412 | 1.910 |
Why?
| | Melanocytes | 9 | 2024 | 65 | 1.870 |
Why?
| | Nitrophenols | 5 | 2017 | 29 | 1.710 |
Why?
| | Biphenyl Compounds | 5 | 2017 | 68 | 1.650 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 4 | 2024 | 39 | 1.440 |
Why?
| | MicroRNAs | 4 | 2020 | 701 | 0.920 |
Why?
| | Cell Line, Tumor | 23 | 2023 | 3540 | 0.870 |
Why?
| | Hair Color | 1 | 2024 | 14 | 0.840 |
Why?
| | Hyperpigmentation | 1 | 2024 | 27 | 0.830 |
Why?
| | Tankyrases | 1 | 2023 | 13 | 0.810 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2024 | 72 | 0.770 |
Why?
| | Cell Culture Techniques | 3 | 2021 | 375 | 0.760 |
Why?
| | Tumor Suppressor Proteins | 3 | 2024 | 321 | 0.720 |
Why?
| | GTP Phosphohydrolases | 2 | 2018 | 93 | 0.670 |
Why?
| | Proto-Oncogene Proteins | 2 | 2018 | 623 | 0.660 |
Why?
| | Spheroids, Cellular | 1 | 2021 | 73 | 0.630 |
Why?
| | Molecular Targeted Therapy | 3 | 2025 | 432 | 0.620 |
Why?
| | Nevus | 1 | 2020 | 26 | 0.610 |
Why?
| | Aniline Compounds | 1 | 2020 | 119 | 0.600 |
Why?
| | Cell Survival | 7 | 2021 | 1098 | 0.520 |
Why?
| | Apoptosis Regulatory Proteins | 3 | 2018 | 186 | 0.520 |
Why?
| | Microtubule-Associated Proteins | 1 | 2018 | 196 | 0.520 |
Why?
| | Hepatitis B Antibodies | 1 | 2016 | 6 | 0.490 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2016 | 19 | 0.490 |
Why?
| | Drug Therapy, Combination | 2 | 2016 | 1047 | 0.490 |
Why?
| | Drug Synergism | 5 | 2017 | 357 | 0.490 |
Why?
| | Hepatitis B virus | 1 | 2016 | 33 | 0.490 |
Why?
| | Genes, ras | 3 | 2008 | 96 | 0.480 |
Why?
| | Mitochondrial Proteins | 1 | 2018 | 262 | 0.480 |
Why?
| | Hepatitis B Vaccines | 1 | 2016 | 43 | 0.480 |
Why?
| | Lentigo | 1 | 2015 | 6 | 0.460 |
Why?
| | Antibody Formation | 1 | 2016 | 294 | 0.440 |
Why?
| | Fenretinide | 1 | 2014 | 3 | 0.440 |
Why?
| | Hyperthermia, Induced | 2 | 2007 | 121 | 0.440 |
Why?
| | Oligopeptides | 1 | 2016 | 269 | 0.440 |
Why?
| | Piperazines | 5 | 2017 | 381 | 0.430 |
Why?
| | Xenograft Model Antitumor Assays | 5 | 2021 | 928 | 0.430 |
Why?
| | Peptide Fragments | 1 | 2018 | 699 | 0.430 |
Why?
| | Gene Expression Regulation, Neoplastic | 8 | 2020 | 1455 | 0.410 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2017 | 427 | 0.410 |
Why?
| | Down-Regulation | 3 | 2012 | 627 | 0.390 |
Why?
| | Cell Proliferation | 7 | 2017 | 2496 | 0.370 |
Why?
| | Mice | 13 | 2024 | 18339 | 0.350 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2011 | 115 | 0.350 |
Why?
| | Alkylating Agents | 1 | 2011 | 24 | 0.350 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2016 | 225 | 0.350 |
Why?
| | Humans | 43 | 2025 | 144759 | 0.350 |
Why?
| | Animals | 18 | 2025 | 38058 | 0.340 |
Why?
| | Dacarbazine | 1 | 2011 | 100 | 0.340 |
Why?
| | Biological Assay | 1 | 2011 | 128 | 0.340 |
Why?
| | Mice, Nude | 5 | 2020 | 682 | 0.320 |
Why?
| | Biomimetic Materials | 1 | 2011 | 76 | 0.320 |
Why?
| | Ultraviolet Therapy | 2 | 2020 | 17 | 0.300 |
Why?
| | Mutation | 8 | 2017 | 4089 | 0.290 |
Why?
| | Vitiligo | 2 | 2020 | 42 | 0.290 |
Why?
| | Leupeptins | 1 | 2008 | 12 | 0.290 |
Why?
| | Skin Pigmentation | 2 | 2020 | 48 | 0.290 |
Why?
| | Proteasome Inhibitors | 1 | 2008 | 40 | 0.290 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2008 | 50 | 0.290 |
Why?
| | Saccharomyces cerevisiae | 5 | 2011 | 579 | 0.270 |
Why?
| | rho GTP-Binding Proteins | 2 | 2020 | 56 | 0.270 |
Why?
| | Indoles | 1 | 2011 | 501 | 0.260 |
Why?
| | Caspases | 5 | 2017 | 232 | 0.260 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2008 | 436 | 0.260 |
Why?
| | Membrane Proteins | 2 | 2016 | 1166 | 0.260 |
Why?
| | Neurofibromin 1 | 2 | 2017 | 26 | 0.250 |
Why?
| | Cell Self Renewal | 2 | 2017 | 53 | 0.250 |
Why?
| | Transfection | 5 | 2012 | 940 | 0.250 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2006 | 56 | 0.240 |
Why?
| | Extracellular Matrix Proteins | 2 | 2006 | 158 | 0.230 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2006 | 132 | 0.230 |
Why?
| | Exome | 2 | 2017 | 227 | 0.230 |
Why?
| | Endoplasmic Reticulum | 1 | 2007 | 266 | 0.230 |
Why?
| | Lovastatin | 1 | 2005 | 37 | 0.220 |
Why?
| | Biotechnology | 1 | 2005 | 46 | 0.220 |
Why?
| | Biomarkers, Tumor | 4 | 2017 | 1313 | 0.210 |
Why?
| | Ankyrin Repeat | 1 | 2023 | 1 | 0.210 |
Why?
| | Poly ADP Ribosylation | 1 | 2023 | 10 | 0.210 |
Why?
| | Equipment Failure Analysis | 1 | 2004 | 128 | 0.200 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2006 | 380 | 0.200 |
Why?
| | Bcl-2-Like Protein 11 | 2 | 2017 | 37 | 0.200 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2018 | 881 | 0.200 |
Why?
| | Phenotype | 3 | 2024 | 3162 | 0.190 |
Why?
| | Pedigree | 1 | 2024 | 514 | 0.190 |
Why?
| | ras Proteins | 1 | 2003 | 150 | 0.190 |
Why?
| | Specimen Handling | 1 | 2004 | 186 | 0.180 |
Why?
| | Biophysics | 1 | 2022 | 74 | 0.180 |
Why?
| | Cell Lineage | 1 | 2024 | 376 | 0.180 |
Why?
| | Uveal Neoplasms | 1 | 2021 | 16 | 0.180 |
Why?
| | Hair Follicle | 2 | 2020 | 48 | 0.170 |
Why?
| | Fungal Proteins | 2 | 1999 | 145 | 0.170 |
Why?
| | Hot Temperature | 1 | 2004 | 407 | 0.170 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 439 | 0.170 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2003 | 557 | 0.160 |
Why?
| | Cell Cycle Proteins | 3 | 2000 | 628 | 0.160 |
Why?
| | Positive Regulatory Domain I-Binding Factor 1 | 1 | 2020 | 17 | 0.160 |
Why?
| | Adult Stem Cells | 1 | 2020 | 39 | 0.160 |
Why?
| | Neoplasm Invasiveness | 3 | 2013 | 508 | 0.160 |
Why?
| | CDC28 Protein Kinase, S cerevisiae | 1 | 1999 | 7 | 0.150 |
Why?
| | beta Catenin | 2 | 2020 | 252 | 0.150 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2016 | 1137 | 0.150 |
Why?
| | Melanoma, Experimental | 2 | 2011 | 108 | 0.140 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2024 | 917 | 0.140 |
Why?
| | Dynamins | 1 | 2018 | 36 | 0.140 |
Why?
| | Female | 14 | 2024 | 78271 | 0.140 |
Why?
| | Ultraviolet Rays | 3 | 2008 | 388 | 0.140 |
Why?
| | Cytokines | 1 | 2006 | 2061 | 0.140 |
Why?
| | Cancer Vaccines | 2 | 2011 | 160 | 0.140 |
Why?
| | Cyclin-Dependent Kinases | 1 | 1999 | 123 | 0.140 |
Why?
| | Saccharomyces cerevisiae Proteins | 2 | 1999 | 419 | 0.130 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2017 | 26 | 0.130 |
Why?
| | Transforming Growth Factor beta | 1 | 2000 | 479 | 0.130 |
Why?
| | Gene Knockout Techniques | 1 | 2017 | 116 | 0.130 |
Why?
| | Zebrafish Proteins | 1 | 2020 | 311 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2017 | 72 | 0.130 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 64 | 0.130 |
Why?
| | Mucous Membrane | 1 | 2017 | 127 | 0.120 |
Why?
| | Genes, erbB-1 | 1 | 2016 | 21 | 0.120 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2016 | 77 | 0.120 |
Why?
| | Pyrroles | 1 | 2017 | 217 | 0.120 |
Why?
| | Disease Models, Animal | 3 | 2018 | 4557 | 0.120 |
Why?
| | Transcription, Genetic | 4 | 2017 | 1496 | 0.120 |
Why?
| | Zebrafish | 1 | 2020 | 528 | 0.120 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 210 | 0.110 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2011 | 529 | 0.110 |
Why?
| | Inflammasomes | 1 | 2017 | 146 | 0.110 |
Why?
| | Signal Transduction | 4 | 2020 | 5226 | 0.110 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2020 | 905 | 0.110 |
Why?
| | Phosphoproteins | 1 | 2017 | 344 | 0.110 |
Why?
| | Genetic Linkage | 1 | 2015 | 273 | 0.110 |
Why?
| | Retinoids | 1 | 2014 | 33 | 0.110 |
Why?
| | Cells, Cultured | 4 | 2020 | 4154 | 0.110 |
Why?
| | Caspase 3 | 2 | 2005 | 238 | 0.100 |
Why?
| | Complementary Therapies | 1 | 2015 | 94 | 0.100 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2014 | 99 | 0.100 |
Why?
| | Machine Learning | 1 | 2020 | 585 | 0.100 |
Why?
| | Prognosis | 3 | 2020 | 4282 | 0.100 |
Why?
| | Genes, Tumor Suppressor | 1 | 2013 | 83 | 0.100 |
Why?
| | Neoplasm Metastasis | 2 | 2013 | 688 | 0.100 |
Why?
| | Up-Regulation | 2 | 2006 | 851 | 0.100 |
Why?
| | Stem Cells | 1 | 2017 | 626 | 0.100 |
Why?
| | Smad1 Protein | 1 | 2012 | 17 | 0.100 |
Why?
| | Genomic Instability | 1 | 2013 | 66 | 0.100 |
Why?
| | Neoplasm Proteins | 2 | 2007 | 442 | 0.090 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2013 | 73 | 0.090 |
Why?
| | Microarray Analysis | 1 | 2012 | 117 | 0.090 |
Why?
| | BRCA1 Protein | 1 | 2013 | 81 | 0.090 |
Why?
| | Alcohol Oxidoreductases | 1 | 2013 | 62 | 0.090 |
Why?
| | Tretinoin | 1 | 2013 | 124 | 0.090 |
Why?
| | Biomedical Research | 1 | 2018 | 710 | 0.090 |
Why?
| | Adult | 6 | 2024 | 40449 | 0.090 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 286 | 0.090 |
Why?
| | Survival Analysis | 1 | 2015 | 1382 | 0.090 |
Why?
| | Disease Progression | 5 | 2020 | 2847 | 0.090 |
Why?
| | Cellular Senescence | 1 | 2013 | 226 | 0.080 |
Why?
| | Annexin A5 | 2 | 2013 | 21 | 0.080 |
Why?
| | Vaccines, Synthetic | 1 | 2011 | 138 | 0.080 |
Why?
| | Genetic Engineering | 1 | 2011 | 93 | 0.080 |
Why?
| | Male | 6 | 2024 | 72315 | 0.080 |
Why?
| | Cell Death | 1 | 2011 | 383 | 0.080 |
Why?
| | RNA Interference | 2 | 2009 | 476 | 0.080 |
Why?
| | Neoplasms | 1 | 2025 | 2875 | 0.080 |
Why?
| | Time Factors | 3 | 2013 | 7173 | 0.080 |
Why?
| | Aldose-Ketose Isomerases | 1 | 2009 | 8 | 0.080 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2009 | 76 | 0.070 |
Why?
| | Protein Structure, Tertiary | 1 | 2011 | 862 | 0.070 |
Why?
| | Precipitin Tests | 2 | 1999 | 93 | 0.070 |
Why?
| | Adenocarcinoma | 1 | 2016 | 928 | 0.070 |
Why?
| | Treatment Outcome | 3 | 2020 | 11679 | 0.070 |
Why?
| | Antioxidants | 2 | 2013 | 549 | 0.070 |
Why?
| | Methionine | 1 | 2009 | 162 | 0.070 |
Why?
| | Anoikis | 1 | 2008 | 30 | 0.070 |
Why?
| | Cell Line, Transformed | 1 | 2008 | 140 | 0.070 |
Why?
| | Biomarkers | 1 | 2020 | 4271 | 0.070 |
Why?
| | Microphthalmia-Associated Transcription Factor | 1 | 2008 | 14 | 0.070 |
Why?
| | Radiation-Protective Agents | 1 | 2008 | 17 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2027 | 0.060 |
Why?
| | Heat-Shock Proteins | 1 | 2007 | 138 | 0.060 |
Why?
| | Cysteine | 1 | 2008 | 210 | 0.060 |
Why?
| | rhoC GTP-Binding Protein | 1 | 2006 | 6 | 0.060 |
Why?
| | Enzyme Induction | 1 | 2006 | 88 | 0.060 |
Why?
| | Growth Substances | 1 | 2006 | 140 | 0.060 |
Why?
| | Models, Animal | 1 | 2008 | 392 | 0.060 |
Why?
| | Molecular Chaperones | 1 | 2007 | 200 | 0.060 |
Why?
| | Antigens, Neoplasm | 1 | 2007 | 271 | 0.060 |
Why?
| | Ethidium | 1 | 2005 | 6 | 0.060 |
Why?
| | Acridine Orange | 1 | 2005 | 4 | 0.060 |
Why?
| | Young Adult | 3 | 2020 | 14105 | 0.060 |
Why?
| | Caspase 7 | 1 | 2005 | 22 | 0.060 |
Why?
| | Dimethylallyltranstransferase | 1 | 2005 | 1 | 0.060 |
Why?
| | Polyisoprenyl Phosphates | 1 | 2005 | 4 | 0.060 |
Why?
| | Risk Assessment | 1 | 2015 | 3671 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2013 | 1499 | 0.060 |
Why?
| | In Situ Nick-End Labeling | 1 | 2005 | 121 | 0.060 |
Why?
| | Jurkat Cells | 1 | 2005 | 114 | 0.060 |
Why?
| | Pravastatin | 1 | 2005 | 43 | 0.060 |
Why?
| | False Positive Reactions | 1 | 2005 | 121 | 0.060 |
Why?
| | Sesquiterpenes | 1 | 2005 | 52 | 0.050 |
Why?
| | Infant, Newborn | 1 | 2016 | 6429 | 0.050 |
Why?
| | Camptothecin | 1 | 2005 | 140 | 0.050 |
Why?
| | Necrosis | 1 | 2005 | 244 | 0.050 |
Why?
| | Molecular Sequence Data | 3 | 2009 | 2930 | 0.050 |
Why?
| | Transcriptional Activation | 1 | 2006 | 383 | 0.050 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2005 | 177 | 0.050 |
Why?
| | Prospective Studies | 1 | 2016 | 7990 | 0.050 |
Why?
| | Cell Adhesion | 1 | 2005 | 455 | 0.050 |
Why?
| | Gene Expression | 2 | 2017 | 1490 | 0.050 |
Why?
| | Reproducibility of Results | 1 | 2011 | 3409 | 0.050 |
Why?
| | Feedback | 1 | 2004 | 181 | 0.050 |
Why?
| | Anticholesteremic Agents | 1 | 2005 | 152 | 0.050 |
Why?
| | Fluorescent Dyes | 1 | 2005 | 329 | 0.050 |
Why?
| | Pregnancy | 1 | 2016 | 7190 | 0.050 |
Why?
| | Cell Hypoxia | 1 | 2003 | 247 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2637 | 0.050 |
Why?
| | Equipment Design | 1 | 2004 | 530 | 0.050 |
Why?
| | fas Receptor | 1 | 2002 | 92 | 0.050 |
Why?
| | Interleukin-1 | 1 | 2006 | 961 | 0.050 |
Why?
| | Cell Division | 2 | 2002 | 766 | 0.050 |
Why?
| | Tumor Cells, Cultured | 2 | 2002 | 919 | 0.050 |
Why?
| | Infant | 1 | 2016 | 10034 | 0.040 |
Why?
| | Inflammation | 1 | 2013 | 2878 | 0.040 |
Why?
| | Mitochondria | 1 | 2008 | 984 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2005 | 824 | 0.040 |
Why?
| | Substrate Specificity | 2 | 1999 | 388 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2006 | 1217 | 0.040 |
Why?
| | Proteomics | 2 | 2009 | 1195 | 0.040 |
Why?
| | Temperature | 1 | 2004 | 679 | 0.040 |
Why?
| | Chromatin | 1 | 2005 | 561 | 0.040 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2023 | 346 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2009 | 2155 | 0.040 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2023 | 630 | 0.040 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2020 | 55 | 0.040 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2005 | 641 | 0.040 |
Why?
| | MART-1 Antigen | 2 | 2011 | 8 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2002 | 459 | 0.040 |
Why?
| | Chromatography, Ion Exchange | 1 | 1999 | 57 | 0.040 |
Why?
| | Chromatography, Affinity | 1 | 1999 | 85 | 0.040 |
Why?
| | Keratinocytes | 1 | 2020 | 248 | 0.040 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2011 | 223 | 0.040 |
Why?
| | Cyclins | 1 | 1999 | 84 | 0.040 |
Why?
| | Hybrid Cells | 1 | 1998 | 49 | 0.040 |
Why?
| | Genetic Complementation Test | 1 | 1998 | 66 | 0.040 |
Why?
| | Immunoblotting | 1 | 1999 | 300 | 0.040 |
Why?
| | Cell Movement | 1 | 2023 | 965 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2003 | 2832 | 0.030 |
Why?
| | Pigmentation | 1 | 2018 | 53 | 0.030 |
Why?
| | Molecular Weight | 1 | 1998 | 327 | 0.030 |
Why?
| | Laser Capture Microdissection | 1 | 2017 | 29 | 0.030 |
Why?
| | NLR Proteins | 1 | 2017 | 8 | 0.030 |
Why?
| | Protein Kinases | 1 | 1999 | 315 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2017 | 251 | 0.030 |
Why?
| | Cell Cycle | 1 | 1999 | 596 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2017 | 402 | 0.030 |
Why?
| | Phosphorylation | 1 | 2000 | 1732 | 0.030 |
Why?
| | Tumor Burden | 1 | 2017 | 319 | 0.030 |
Why?
| | Survival Rate | 1 | 2020 | 2089 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 183 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2017 | 442 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2016 | 406 | 0.030 |
Why?
| | Middle Aged | 4 | 2020 | 35875 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 549 | 0.030 |
Why?
| | Monophenol Monooxygenase | 1 | 2013 | 7 | 0.030 |
Why?
| | Microscopy, Phase-Contrast | 1 | 2013 | 18 | 0.020 |
Why?
| | Melanins | 1 | 2013 | 17 | 0.020 |
Why?
| | Spectrophotometry | 1 | 2013 | 61 | 0.020 |
Why?
| | Catalase | 1 | 2013 | 130 | 0.020 |
Why?
| | Administration, Topical | 1 | 2013 | 150 | 0.020 |
Why?
| | Aged | 3 | 2020 | 25913 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2013 | 163 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2020 | 2050 | 0.020 |
Why?
| | Precision Medicine | 1 | 2016 | 457 | 0.020 |
Why?
| | Superoxide Dismutase | 1 | 2013 | 301 | 0.020 |
Why?
| | Computational Biology | 1 | 2016 | 680 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2000 | 2608 | 0.020 |
Why?
| | DNA Repair | 1 | 2013 | 256 | 0.020 |
Why?
| | DNA Damage | 1 | 2013 | 430 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2017 | 3604 | 0.020 |
Why?
| | S-Adenosylmethionine | 1 | 2009 | 59 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2009 | 193 | 0.020 |
Why?
| | Mice, Inbred C57BL | 2 | 2011 | 5992 | 0.020 |
Why?
| | Mice, Hairless | 1 | 2008 | 47 | 0.020 |
Why?
| | Molecular Structure | 1 | 2009 | 499 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2007 | 37 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2009 | 766 | 0.020 |
Why?
| | Histones | 1 | 2013 | 669 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5408 | 0.020 |
Why?
| | 3' Untranslated Regions | 1 | 2008 | 152 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 2008 | 510 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2007 | 161 | 0.020 |
Why?
| | Genome, Human | 1 | 2008 | 422 | 0.010 |
Why?
| | Spleen | 1 | 2007 | 508 | 0.010 |
Why?
| | Kaplan-Meier Estimate | 1 | 2007 | 965 | 0.010 |
Why?
| | Alleles | 1 | 2008 | 879 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2017 | 8265 | 0.010 |
Why?
| | Base Sequence | 1 | 2008 | 2190 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2007 | 1370 | 0.010 |
Why?
| | Interferon-gamma | 1 | 2007 | 784 | 0.010 |
Why?
| | Cathepsin D | 1 | 2003 | 19 | 0.010 |
Why?
| | CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2002 | 19 | 0.010 |
Why?
| | Fas Ligand Protein | 1 | 2002 | 60 | 0.010 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2003 | 381 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2007 | 1129 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2008 | 1782 | 0.010 |
Why?
| | Adolescent | 1 | 2020 | 22428 | 0.010 |
Why?
| | Protein Processing, Post-Translational | 1 | 2003 | 477 | 0.010 |
Why?
| | Receptors, Cell Surface | 1 | 2002 | 377 | 0.010 |
Why?
| | Child | 1 | 2020 | 22633 | 0.010 |
Why?
| | Mass Spectrometry | 1 | 2003 | 750 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 496 | 0.010 |
Why?
| | Apc6 Subunit, Anaphase-Promoting Complex-Cyclosome | 1 | 1999 | 1 | 0.010 |
Why?
| | Vaccination | 1 | 2007 | 1423 | 0.010 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 1999 | 132 | 0.010 |
Why?
| | Nuclear Proteins | 1 | 2003 | 748 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2002 | 737 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 1999 | 675 | 0.010 |
Why?
|
|
Shellman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|